Illumina Integrates XLEAP-SBS Chemistry Across NextSeq 1000/2000 Instruments
In June 2024, Illumina Inc., a global leader in DNA sequencing and array-based technologies, has announced the full integration of its advanced XLEAP-SBS chemistry into all reagents for its NextSeq 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments.
In June 2024, Illumina Inc., a global leader in DNA sequencing and array-based technologies, announced the full integration of its advanced XLEAP-SBS chemistry into all reagents for its NextSeq 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments. "They are excited to deliver for their NextSeq 1000/2000 customers improved sequencing with faster run times, better quality, and higher output all at a lower cost per kit," said the Head of Global Product Management at Illumina. "XLEAP-SBS chemistry on NextSeq 1000/2000 will enable labs to perform bigger NGS projects without raising the budget, and facilitate greater adoption of multiomic approaches."
In March, the company introduced its P4 flow cell, offering a maximum output of 540 Gb with XLEAP-SBS chemistry for the NextSeq 2000. Now, they have announced the availability of the XLEAP-SBS P1, P2, and P3 flow cells. This cutting-edge chemistry delivers faster, higher-quality sequencing, reducing turnaround times by approximately 20%.
Early-access users have expressed satisfaction with the improvements. Head of Biomics at the Institut Pasteur, noted, "They were very happy with the quantity and quality of the reads. The Q is very close to Q40, and the stability is a game-changer for Illumina. From the first base to the last base, they improved the quality of the run quite a lot."
The NextSeq 1000 and NextSeq 2000 Systems are versatile mid-throughput sequencers, supporting applications like single-cell, whole-exome, and RNA sequencing.
Related Reports:
